Perioperative ARDS and lung injury: for anaesthesia and beyond

Robert Wise*, David Bishop*, Gavin Joynt* and Reitze Rodseth

*Corresponding author, email: Robert.Wise@kznhealth.gov.za

Introduction
Pulmonary complications after surgery are common and are associated with significant cost. These complications lengthen hospitalisation, ventilation, and time spent in intensive care, and profoundly increase the risk of mortality and significant morbidity. Acute respiratory distress syndrome (ARDS), a life-threatening respiratory disease process characterised by hypoxaemia and reduced lung compliance, is one of the more serious pulmonary complications. The development of ARDS or the related entity of lung injury is associated with prolonged hospitalisation, ventilation, and time spent in intensive care, and profoundly increases the risk of mortality and significant morbidity. Patients with, or at risk of ARDS and lung injury, must be identified, optimised and managed with sound intraoperative principles (particularly ventilation and fluid management) – with the specific aim of limiting harm. This review will focus on the diagnosis, pathophysiology, prevention and management of ARDS and lung injury in the perioperative period.

Keywords: acute lung injury, anaesthesia, ARDS, ventilation

Pathophysiology
The pathophysiological mechanisms of ARDS vary depending on the causative pathology, but several common inflammatory pathways that subsequently cause alveolar damage are involved. These inflammatory processes cause endothelial damage, disrupt normal protective barriers, inhibit surfactant production and function, impair coagulation, and inhibit normal alveolar immunological responses. Increased vascular permeability and damage to the pulmonary microvasculature results in fluid and neutrophil leakage into alveolar and interstitial tissue. The result is impaired gas exchange due to damaged alveolar-capillary membranes, and the two hallmark features of ARDS: hypoxaemia and reduced lung compliance. These lung changes are rarely homogenous and result in areas of disease interspersed with normal lung units. The stretching at the interface of diseased and healthy lung also causes excessive shear stress and perpetuates the release of inflammatory mediators and exacerbates local and systemic inflammation.

Diagnostic criteria
In 2012 the Berlin Definitions replaced the 1994 American-European Consensus Conference (AECC) definition of ‘acute lung injury’ (ALI). The term ALI was discarded and the distinction between primary and secondary ALI (largely related to onset time) was integrated into a new ARDS definition. The Berlin Definitions, compiled by the European Society of Intensive Care Medicine and endorsed by the American Thoracic Society and the Society of Critical Care Medicine, recognise three stages of severity based on the PaO2/FiO2 ratio. Four factors are involved in making the diagnosis:

(a) Timing – onset over less than seven days;
(b) Chest x-ray (or computerised tomography [CT] scan) changes – bilateral opacification not explained by alternative lung pathology;
(c) Origin of oedema – must not be fully explained by cardiac failure or fluid overload, and an objective assessment (cardiac ultrasound) should be performed if there is uncertainty;
(d) Severity of hypoxaemia, graded according to PF ratio (pO2 in mmHg), with a minimum positive end-expiratory pressure (PEEP) of 5 cm H2O (mild 200–300, moderate (100–200) or severe (< 100)).

Anaesthetic management strategies for patients with ARDS
Several advancements have improved ARDS outcomes. These include better ventilation strategies and care bundles, transfusion and fluid management, and early appropriate management of sepsis. Patients with, or at risk of ARDS, must be identified, optimised and managed with sound intraoperative principles.
(particularly ventilation and fluid management) – with the specific aim of limiting harm.

Anaesthesiologists caring for patients with, or at risk of ARDS, should aim to:
(1) Provide optimal ventilation and anaesthesia without compromising the cardiovascular system;
(2) Ventilate patients with lung protective strategies to limit inflammatory processes;
(3) Avoid unnecessary intravenous fluids that contribute to extravascular lung water accumulation; and
(4) Promote recovery and postoperative mobilisation.

Despite a lack of data showing that these principles improve outcomes in healthy patients, it seems prudent to adopt these strategies in all ventilated perioperative patients.

A. Preoperative management
Preoperative objectives include the identification of patients at risk for developing ARDS (using general risk factors and scoring systems) and optimisation of these patients where possible. These measures are outlined below.

(1) Identification of general risk factors for developing ARDS (Table 1).

Table 1: General risk factors for developing ARDS¹

<table>
<thead>
<tr>
<th>Direct risk factors</th>
<th>Indirect risk factors</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pneumonia</td>
<td>Non-pulmonary sepsis</td>
</tr>
<tr>
<td>Aspiration of gastric contents</td>
<td>Major trauma</td>
</tr>
<tr>
<td>Inhalational injury</td>
<td>Pancreatitis</td>
</tr>
<tr>
<td>Pulmonary contusion</td>
<td>Severe burns</td>
</tr>
<tr>
<td>Pulmonary vasculitis</td>
<td>Non-cardiogenic shock</td>
</tr>
<tr>
<td>Drowning</td>
<td>Drug overdose</td>
</tr>
<tr>
<td></td>
<td>Multiple transfusions or TRALI</td>
</tr>
</tbody>
</table>

Notes: ARDS = acute respiratory distress syndrome; TRALI = transfusion-associated acute lung injury.

(2) Risk prediction scores for ARDS.

(a) Several ARDS risk prediction models exist and vary from specific surgical populations (predominantly cardiothoracic)¹⁶⁻²⁵ to general surgical patients.²⁶⁻²⁷ The Surgical Lung Injury Prediction 2 model (SLIP-2) is a mathematical model that predicts patients at risk of developing early postoperative lung injury (Table 2). The score performed well in distinguishing patients that develop early lung injury from those that do not (AUC [95% CI], 0.84 [0.81, 0.88]).²⁷ Kor et al.²⁷ identified nine independent ARDS predictors.

(b) The Lung Injury Prediction (LIP) Score is an alternative model initially developed for all patients, and validated in surgical critical care patients.²⁸⁻²⁹ The LIP Score performed well in this surgical population (receiver operating characteristic [ROC] area under the curve of 0.79, with good calibration).

(c) More recently, early oxygen saturation to fraction of inspired oxygen ratio (within 6 hours of hospital admission) has been shown to be an independent indicator of ARDS development in patients at risk.³⁰

B. Intraoperative management
General anaesthesia has several negative consequences on the respiratory system:

(i) Basal atelectasis (due to positioning, high inspired FiO₂, and reduced functional residual capacity).
(ii) Loss of muscle tone and subsequent decreased negative pressure lung expansion.
(iii) Decreased minute ventilation.
(iv) Closing capacity nearing functional residual capacity.
(v) Volatile anaesthetic-induced inhibition of hypoxic pulmonary vasoconstriction leading to increased intrapulmonary shunting.
(vi) Increased alveolar dead space ventilation due to atelectasis and alterations in perfusion characteristic in the supine and anaesthetised position.
(vii) Blunting of the normal responses to hypercarbia.³⁷

Ventilating patients with ARDS undergoing general anaesthesia adds even more complexity.

Table 2: Independent ARDS predictors used in the Surgical Lung Injury Prediction 2 model (SLIP-2)

<table>
<thead>
<tr>
<th>SLIP-2 model predictors of ARDS²⁷</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sepsis</td>
</tr>
<tr>
<td>High-risk aortic vascular surgery</td>
</tr>
<tr>
<td>High-risk cardiac surgery</td>
</tr>
<tr>
<td>Emergency surgery</td>
</tr>
<tr>
<td>Cirrhosis</td>
</tr>
<tr>
<td>Admission location other than home</td>
</tr>
<tr>
<td>Increased respiratory rate (20–29 and &gt; 30 breaths/min)</td>
</tr>
<tr>
<td>FiO₂ greater than 0.35</td>
</tr>
<tr>
<td>SpO₂ less than 95%</td>
</tr>
</tbody>
</table>

Notes: ARDS = acute respiratory distress syndrome; FiO₂ = fraction of inspiratory oxygen; SpO₂ = blood oxygen saturation.

(d) Several biomarkers of alveolar epithelial injury, vascular endothelial injury and increased coagulation in patients with ARDS correlate with morbidity and mortality.²⁸⁻³¹ Biomarker panels may also help differentiate severe sepsis-induced ARDS from trauma-induced lung injury.³²⁻³⁴ However, their clinical utility for diagnosis and prognostication is unproven.

(3) Optimisation

(a) Early recognition of underlying respiratory infections and identification of causative pathogens is an essential part of preoperative management. Consideration should be given to possible bacterial, fungal and viral infections. Early empiric antibiotic therapy is advisable in overtly septic patients, with subsequent de-escalation to directed therapy in response to culture results.

(b) Bedside lung ultrasound may offer additional diagnostic information as shown in a recent pilot study combining ultrasound with SpO₂/FiO₂ ratios.³⁵ It is also a useful adjunct to help differentiate ARDS from cardiogenic pulmonary oedema.³⁶

(c) Routine approaches to reduce gastric aspiration and ventilator-associated pneumonia should be employed.
(1) Ventilation

Mechanical forces generated by positive pressure ventilation contribute to ventilator-induced lung injury and ARDS. This is particularly severe at the interface between normal lung units and diseased lung units. Management strategies attempt to limit the amount of stretching, strain and biotrauma generated at these interfaces. Newer concepts in reducing ventilator-induced lung injury include minimising alveolar damage through the reduced transfer of energy to at-risk lung units. Recent focus has moved away from traditional concepts such as barotrauma and volutrauma, towards mechanical and driving power. Driving pressure (the plateau pressure minus PEEP) is once such theory that explores the relationship between reduced energy transfer and improved mortality in perioperative and ARDS patients. Although further research is required, it is a promising field that is supported by both physiological explanations and retrospective data analysis. Mechanical power is a concept that attempts to unify multiple ventilator-related causes of lung injury into a single variable. Ventilator indices such as tidal volume, driving pressure, flow, PEEP and respiratory rate are expressed in an equation that quantifies mechanical power, measured in joules. Initial experimental work has confirmed that with rising power there is a higher likelihood of developing ventilator-induced lung injury (VILI). Driving power and mechanical power are increasingly being suggested as new targets in ventilator strategies aimed at reducing VILI. A detailed discussion is beyond the scope of this review, but further reading is advised in this area.

(a) $\text{FiO}_2$: The majority of evidence from ICU patients now recommends targeting an $\text{FiO}_2$ resulting in a $\text{SpO}_2$ of between 88 and 95%. Additional research is needed to determine the net benefits related to potential lung toxicity caused by unnecessarily high concentrations of inspired oxygen (such as diffuse alveolar damage, direct airway injury, increasing dead space), and the potential benefits on neurocognitive outcomes when targeting normoxaemia.

(b) Positive end expiratory pressure (PEEP): Selecting the ideal PEEP is challenging. PEEP maintains open alveolar units, and potentially avoids repeated opening and closing of alveoli and interfaces between collapsed and open units. This minimises shear forces and bioruma experienced in an unevenly atelectatic lung. However, in heterogeneous affected lungs, where PEEP may be beneficial in some lung units, excessive PEEP may result in overdistension. It may be reasonable to apply a PEEP of 10 cm H$_2$O at the start of ventilation. Additionally, PEEP at less than 10 cm H$_2$O may be used to improve oxygenation without overdistending and exacerbating lung injury.

(c) Tidal volumes (TV): Increasing data support low tidal volume ventilation in patients with established ARDS. Despite a lack of randomised control trials showing a related decrease in postoperative pulmonary complications, low tidal volumes are likely to reduce the shear stresses imposed by PPV within diseased lung regions, and this approach has the potential to improve outcomes. Increasing importance is being placed on the measurement and control of the driving pressure (ratio between tidal volume and compliance, or plateau pressure minus PEEP). Tidal volumes of 6–8 ml/kg (importantly, ideal ventilatory body weight) should be targeted, with a low plateau pressure (< 16 cm H$_2$O), and preferably a low ΔP (< 13 cm H$_2$O). Tidal volumes of 4–5 ml/kg or less should be targeted for one lung ventilation. If achieving ventilator targets described above does not allow normalisation of $p_{\text{CO}_2}$, permissive hypercapnia in the absence of raised intracranial pressure or severe right heart failure should be allowed. The physiological benefits of hypercapnia include a rightward shift of the oxygen-haemoglobin dissociation curve, increased cardiac output and an anti-inflammatory action.

(d) Mode of ventilation: The mode of ventilation does not appear to influence ARDS outcomes.

(e) Recruitment manoeuvres: Recruitment manoeuvres are controversial, being recommended by some and avoided by those supporting ‘intraoperative permissive atelectasis’. This new concept suggests recruitment manoeuvres should not be routine, particularly in severe ARDS. Recruitment manoeuvres may also be associated with significant haodynamic instability due to effects on right ventricular preload and afterload. Recommendations support individualised practice and avoidance of unnecessary attempts to expand lung units and the worsening of biotrauma and atelectrauma. The benefit of recruitment manoeuvres on patient outcome remain inconclusive, and, as a recent publication suggests, may even increase mortality in patients with moderate to severe ARDS.

(f) Fluid management:

(i) Although maintaining adequate tissue perfusion is important, excess intravenous fluid potentially worsens hypoxaemia, as leakage through a dysfunctional endothelial lung barrier increases extravascular lung water. Intravenous fluids should be given judiciously, guided by regular and repeated volume assessments and assessment of fluid responsiveness. Dynamic markers of fluid responsiveness are superior to static markers and should be incorporated in the routine assessment of perioperative patients.

(ii) Blood product transfusions (red blood cells, plasma and platelets) have been identified as risk factors for ARDS. In the ICU and when possible in the operating room, a restrictive transfusion strategy with a haemoglobin transfusion trigger of 7 g/dl and target haemoglobin of > 7 g/dl should be used. Transfusion-related acute lung injury has been linked to plasma containing blood products (platelets, fresh frozen plasma). While efforts in the developed world aim to screen for high-risk donors, this is usually not possible in the developing world.

(2) Anaesthetic choices

(a) Inhalational anaesthetics: In animal models, volatile anaesthetic agents protect against the damage caused during ischaemic-reperfusion injury. The benefit may be multifactorial and includes protection against endothelial glycolcalyx degradation, ischaemic pre-conditioning,
and even immune-modulating effects (inhibition of pro-inflammatory mediators including IL-8, IL-10, and TNF). 36−38

(b) There is little evidence to support one type of anaesthetic over another. Volatile anaesthetic agents do inhibit hypoxic pulmonary vasoconstriction, but carry potential advantages mentioned above. Intravenous agents, such as propofol, may worsen endothelial function when given in overdose, but this requires further research. 39,47

(c) There is little evidence to guide the choice of anaesthesia with a view to reducing the postoperative complications of ARDS. However, a general anaesthetic is likely to be appropriate for most ARDS patients, as management of PEEP and TV generally requires tracheal intubation. There is some evidence supporting the approach of a combined general anaesthetic and neuraxial technique for postoperative analgesia as it has been shown to decrease the incidence of postoperative pneumonia and respiratory failure – potential triggers for ARDS. 40−42 although the benefits of neuraxial block and postoperative epidural are not universal. 43

Table 3: Modalities of therapy investigated for ARDS management

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Corticosteroids 35−37,46</td>
<td>Identification of 21 microRNA has suggested steroid-sensitive and steroid-independent mechanisms in the development of ARDS. This may account for different responses to the use of corticosteroids in previous studies</td>
</tr>
<tr>
<td>Inhaled vasodilators 36,47</td>
<td>Nitric oxide has vasodilatory effects on pulmonary vasculature, and improves arterial oxygenation, but its use has not demonstrated mortality or significant outcome benefits. Its use is complicated by high costs and increased renal dysfunction</td>
</tr>
<tr>
<td>Muscle relaxants 36−38,49</td>
<td>Short-term use of muscle relaxation (up to 48 h) for patients with severe ARDS may reduce mortality risk and reduce ventilator-associated lung injury. This may be mediated by reducing transpulmonary pressures during mechanical ventilation and reducing oxygen consumption, but this strategy requires further investigation</td>
</tr>
<tr>
<td>ECMO 48</td>
<td>ECMO has shown promising results in uncontrolled reports of its use in the management of severe ARDS. The role of this expensive therapy in ARDS treatment and in the transport of those with severe ARDS requires further investigation</td>
</tr>
<tr>
<td>Aspirin 31</td>
<td>Aspirin may have positive effects on platelets that play an active role in the development of ARDS. The Lung Injury Prevention Study with Aspirin, a phase II trial, did not show any outcome benefit</td>
</tr>
<tr>
<td>Aerosolised beta-2-agonists</td>
<td>These agents have previously been effective in reducing pulmonary oedema by stimulating cyclic adenosine monophosphate-dependent alveolar fluid clearance. Initial studies demonstrated harm in patients with ARDS. 42−46 However, a recent study showed favourable results with inhaled budesonide and formoterol. Patients had improved oxygenation, lower rates of acute respiratory failure and ARDS. 47 This therapy appears promising</td>
</tr>
<tr>
<td>Keratinocyte growth factor and mesenchymal stem cells</td>
<td>Keratinocyte growth factor (KGF) is expressed by mesenchymal cells and appears to promote cell repair via several mechanisms including stimulating type-2 pneumocyte development, increased surfactant production, DNA repair, and improved alveolar fluid clearance. 48−50 The effects of KGF may explain the possible benefits of mesenchymal stem cells in ARDS. Researchers are currently investigating the role of intravenous KGF in patients with ARDS, and the immunomodulating role of mesenchymal stem cells 51</td>
</tr>
<tr>
<td>Surfactant</td>
<td>Surfactant inhibition and degradation is an important contributor to the pathogenesis of ARDS. Although successful in neonates and infants, multiple large trials in adults failed to show improved clinical outcomes, despite reports of transient improvements in oxygenation and lung function. There is a continued search for a better exogenous surfactant replacement therapy 52−56</td>
</tr>
<tr>
<td>Beta-blockers</td>
<td>The theoretical benefit of beta-blockers in ARDS involves suppression of the overstimulated sympathetic response that may negatively affect pulmonary vasculature. 57 Some benefit has been demonstrated in a porcine endotoxin shock model; however, further RCTs are required to understand benefit 58</td>
</tr>
</tbody>
</table>

Notes: ARDS = acute respiratory distress syndrome, ECMO = extracorporeal membrane oxygenation, DNA = deoxyribonucleic acid.
extravascular lung water extravasation. The authors of a recent review emphasise the importance of ensuring euvalaemia, without unnecessary use of intravenous fluid administration. Bedside echocardiography, transpulmonary thermodilution, and inotropic support may provide additional monitoring information. Right ventricular ventilation protection strategies include minimising driving pressures, providing PEEP and ensuring adequate oxygenation.

Questions and future developments

Table 3 outlines several potential new strategies based on putative pathophysiological mechanisms for the management of ARDS. None have been shown to provide a definitive clinical benefit.

Prone positioning may benefit oxygenation due to the heterogenous atelectasis and consolidation seen in ARDS. Despite mortality benefit in the PROSEVA and other trials, its use in the perioperative period is unrealistic in most circumstances.

Conclusion

Lung injury is a common pathology facing anaesthesiologists and accounts for significant postoperative pulmonary complications. Pulmonary and systemic complications can possibly be limited with appropriate ventilatory, haemodynamic and preoperative and postoperative critical care management bundles. New research is exploring multiple approaches to preventing and treating ARDS. These include optimisation of mechanical ventilation settings to minimise injury from positive pressure ventilation (pressures and volumes), pathophysiological mechanisms (inflammatory mediation), and supportive care (fluid therapy), and even alternative methods of respiratory support (ECMO).

Summary and learning points

1. Anaesthesiologists can play a potentially important role in preventing ARDS occurring postoperatively by applying preventive strategies, and minimising the complications of mechanical ventilation in patients with ARDS presenting for operation.

2. ARDS management strategies should be implemented throughout the preoperative, intraoperative and postoperative periods.

3. Ventilation goals in patients with ARDS presenting for anaesthesia should include: minimise $F_O_2$, to maintain $Sp_O_2$ above 88%; appropriate PEEP to avoid atelectasis, but sufficient to prevent shear stress; consider lowering PEEP if the driving pressure is high, particularly if increasing PEEP increases driving pressure, or there are other signs of overdistension present; maintain low tidal volumes (6 ml/kg ideal body weight); a plateau pressure < 16 cmH$_2$O (maximum 30 cmH$_2$O); and a low $\Delta P$ (< 13 cm H$_2$O), even if the resulting low TV requires permissive hypercapnia.

4. Avoid excessive intraoperative transfusion with goal of targeting 7 g/dl in the postoperative ICU period.

5. Volatile anaesthetics may provide a theoretical protective function, despite the negative effects on hypoxic pulmonary vasoconstriction.

6. Haemodynamic stability should be achieved though continuous volume status assessment and judicious inotropic therapy. Utilisation of bedside investigations such as echocardiography, and transpulmonary thermodilution/cardiac output monitoring may provide additional guidance for fluid and vasopressor management.

Disclosure statement – No potential conflict of interest was reported by the authors.

ORCID

Robert Wise http://orcid.org/0000-0001-5237-5582
Gavin Joynt http://orcid.org/0000-0002-5823-3435
Reitze Rodseth http://orcid.org/0000-0002-3779-7805

References


